All In Biotech

Drug Trial Radar · NCT06319820

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 641 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

641

Planned (sponsor's estimate)

Start

Apr 18, 2024

Primary completion

Jun 28, 2028

Study completion Dec 31, 2032

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Mar 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.

Conditions

  • Non-Muscle Invasive Bladder Neoplasms

Interventions

  • TAR-210Combination product

    TAR-210 will be administered intravesically.

  • GemcitabineDrug

    Gemcitabine will be administered intravesically.

  • MMCDrug

    MMC will be administered intravesically.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease Free Survival (DFS)Time frame: From randomization to the date of the first documented recurrence, disease progression or death (approximately 4 years and 2 months)

Locations

193 sites in 20 countries. Site status is shown where the registry gives one.

  • Arkansas Urology

    Little Rock, Arkansas · Completed

  • Genesis Research LLC

    Los Alamitos, California · Active not recruiting

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California · Active not recruiting

  • University of California Irvine Medical Center

    Orange, California · Active not recruiting

  • Om Research LLC

    San Diego, California · Active not recruiting

  • Genesis Research LLC 1

    Sherman Oaks, California · Completed

  • University of Colorado Cancer Center Anschultz Cancer Pavilion

    Aurora, Colorado · Completed

  • Colorado Clinical Research

    Lakewood, Colorado · Active not recruiting

  • Mercy Research

    San Luis, Colorado · Completed

  • Specialty Clinical Research of St Louis

    San Luis, Colorado · Active not recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Active not recruiting

  • Northwestern University

    Chicago, Illinois · Completed

  • First Urology

    Jeffersonville, Indiana · Completed

  • Wichita Urology Group

    Wichita, Kansas · Active not recruiting

  • Ochsner Health System

    New Orleans, Louisiana · Active not recruiting

  • Chesapeake Urology Research Associates

    Hanover, Maryland · Completed

  • Brigham And Women's Hospital

    Boston, Massachusetts · Completed

  • Karmanos Cancer Institute

    Detroit, Michigan · Active not recruiting

  • Comprehensive Urology

    Royal Oak, Michigan · Active not recruiting

  • The Urology Center, PC

    Omaha, Nebraska · Active not recruiting

  • Cancer Institute Of New Jersey

    New Brunswick, New Jersey · Active not recruiting

  • Integrated Medical Professionals

    New York, New York · Completed

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Active not recruiting

  • Associated Medical Professionals of Ny

    Syracuse, New York · Active not recruiting

  • SUNY Upstate Med Univ

    Syracuse, New York · Active not recruiting

  • Levine Cancer Institute

    Charlotte, North Carolina · Active not recruiting

  • Associated Urologists of North Carolina

    Raleigh, North Carolina · Active not recruiting

  • MidLantic Urology

    Bala-Cynwyd, Pennsylvania · Completed

  • Keystone Urology Specialists

    Lancaster, Pennsylvania · Active not recruiting

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina · Active not recruiting

  • The Conrad Pearson Clinic

    Germantown, Tennessee · Active not recruiting

  • University of Tennessee Medical Center

    Knoxville, Tennessee · Completed

  • Urology Associates

    Nashville, Tennessee · Active not recruiting

  • Urology Austin

    Austin, Texas · Active not recruiting

  • Urology Clinics of North Texas

    Dallas, Texas · Active not recruiting

  • UT Southwestern

    Dallas, Texas · Completed

  • Houston Metro Urology

    Houston, Texas · Active not recruiting

  • Spokane Urology

    Spokane, Washington · Active not recruiting

  • Hospital Sirio Libanes

    Buenos Aires, Argentina · Active not recruiting

  • Investigaciones Clinico Moleculares (ICM)

    Chabas, Argentina · Active not recruiting

Showing 40 of 193 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.